Antigen-binding fragments specific for dendritic cells, compositions and methods of use thereof antigens recognized thereby and cells obtained thereby
AssigneeMiltenyi Biotech GmbH
InventorsJuergen Schmitz, Andrzej Dzionek, David Buck
Life of this patent
Estimating the term…
Abstract
The invention provides antigen-binding fragments specific for dendritic cells and effective in treatment and/or diagnosing a variety of disorders. Methods of use are also provided as are methods for screening for additional such antigen-binding fragments and the products obtained thereby.
Claims22
1-154. (canceled)
A cell composition enriched for human dendritic cells that express BDCA-4 (neuropilin-1/CD304).
An ex vivo or in vitro dendritic cell labeled with an antibody that binds BDCA-4 (neuropilin-1/CD304), or antigen-binding fragment thereof, or an ex vivo or in vitro population of dendritic cells so labeled.
A method for isolating or enriching for dendritic cells from a mixture of human cells:
- a) obtaining a mixture of human cells;
- b) contacting cells in the mixture with an antibody that binds BDCA-4 (neuropilin-1/CD304), or antigen-binding fragment thereof, under conditions in which the antibody or antigen-binding fragment labels BDCA-4+ dendritic cells;
- and
- c) separating dendritic cells bound by the antibody or antigen-binding fragment from other cells in the mixture.
A method of modulating dendritic cell cytokine production comprising the steps of isolating a substantially pure population or subpopulation of dendritic cells based on binding of an antigen binding fragment specific for BDCA-4 (neuropilin-1/CD304);
- and treating the cells with an agent that modulates dendritic cell cytokine production.
Dependencies are inferred from the claim text.